Skip to content

A randomized double-blind placebo-controlled trial to investigate the effect of invigorating qi and detoxicating therapy on Th1/Th2 balance shift in high PM2.5 exposed population in Chengdu subway

A randomized double-blind placebo-controlled trial to investigate the effect of invigorating qi and detoxicating therapy on Th1/Th2 balance shift in high PM2.5 exposed population in Chengdu subway

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001293
Enrollment
Unknown
Registered
2025-06-27
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic airway inflammation

Interventions

OMEGA-3 Fatty Acid Group:OMEGA-3 Fatty Acid Oral
GDQ:Ganduqing Oral

Sponsors

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: People with high exposure to PM2.5 1) 18-65 years old continuous on-the-job for = 2 years working = 6 hours per day 2) No hormones and traditional Chinese medicine preparations were taken in the past 3 months 3) Agree to join the study and sign the informed consent form Low exposed population The staff in the subway office (air conditioning device equipped with PM2.5 filter) are the same as the highly exposed population. 4.2 Exclusion Criteria 1) PM2.5 mask wearer 2) Smoker history 3) Patients allergic to seafood and traditional Chinese medicine 4) Pregnant and lactating patients

Exclusion criteria

Exclusion criteria: 1) PM2.5 mask wearer 2) Smoker history 3) Patients allergic to seafood and traditional Chinese medicine 4) Pregnant and lactating patients

Design outcomes

Primary

MeasureTime frame
Pulmonary function;

Secondary

MeasureTime frame
Intestinal flora;Serum Th1/Th2 cells;COOP/WONCA Functional Scale;Quality of Life Evaluation Form;Balance index (IFN-?/IL-4) and secreted factor (IFN-?, IL-4, IL-12, IL-6) levels;

Countries

China

Contacts

Public ContactWu Yongcan

Chengdu University of Traditional Chinese Medicine

406917086@qq.com18623116658

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026